Curis Inc. CRIS
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Curis Inc. (CRIS) is a healthcare company listed in the US with a market value of about $3M. In fiscal year 2025 it had revenue of $9M and net income of -$8M, a net margin of -80.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -3% a year, a 5-year average ROIC of -217%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.
About Curis
Curis is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $10M in 2014 to $9M in 2025, a decline of about 0.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 182% over three years (dilution for shareholders). It spends 299% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $11M | $10M | $10M | $11M | $11M | $10M | $10M | $10M | $8M |
| Net income | -$8M | -$43M | -$47M | -$57M | -$45M | -$30M | -$32M | -$33M | -$53M | -$60M |
| Free cash flow | — | — | -$38M | -$55M | -$38M | -$26M | -$26M | -$30M | -$49M | -$36M |
| EPS (diluted) | $-1.16 | $-13.76 | $-17.92 | $-24.28 | $20.00 | $-24.40 | $-38.80 | $-39.20 | $-71.60 | $-90.00 |
| Net margin | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% | -276.0% | -321.3% | -312.4% | -538.7% | -802.6% |
| ROIC | -63.7% | -779.9% | -123.3% | -83.0% | -34.7% | -14.2% | — | -74.8% | -60.0% | -93.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $30.33, 6716% above the current price; targets range from $6.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $-8.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Curis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Curis pay a dividend?
Not currently.
Is Curis a good stock to buy?
We do not give buy or sell advice. Curis scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.